VERV

Verve Therapeutics Inc

13.34 -0.59 (-4.24%)

纳斯达克（NASDAQ）的延时价格美元市场休市

交易

卖

13.29

买

13.36

热门

@DeepNews

e投睿

6天前

$VERV (Verve Therapeutics Inc) Verve Therapeutics (NASDAQ:VERV) Lifted to Hold at Zacks Investment Research Verve Therapeutics (NASDAQ:VERV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. www.defenseworld.net/2022/05/18/verve-therapeutics-nasdaqverv-lifted-to-hold-at-zacks-investment-research-2.html

翻译

Verve Therapeutics (NASDAQ:VERV) Lifted to Hold at Zacks Investment Research

www.defenseworld.net

Verve Therapeutics (NASDAQ:VERV – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic […]

@DeepNews

e投睿

11天前

$VERV (Verve Therapeutics Inc) FY2022 EPS Estimates for Verve Therapeutics, Inc. (NASDAQ:VERV) Cut by Analyst Verve Therapeutics, Inc. (NASDAQ:VERV) – Equities researchers at Jefferies Financial Group cut their FY2022 earnings estimates for shares of Verve Therapeutics in a research report issued... 显示更多

翻译

FY2022 EPS Estimates for Verve Therapeutics, Inc. (NASDAQ:VERV) Cut by Analyst

www.defenseworld.net

Verve Therapeutics, Inc. (NASDAQ:VERV – Get Rating) – Equities researchers at Jefferies Financial Group cut their FY2022 earnings estimates for shares of Verve Therapeutics in a research report issued on Tuesday, May 10th. Jefferies Financial Group analyst E. Yang now expects that the company will earn ($2.91) per share for the year, down from their […]

@DeepNews

e投睿

12天前

$VERV (Verve Therapeutics Inc) Verve Therapeutics (NASDAQ:VERV) Lifted to Hold at Zacks Investment Research Verve Therapeutics (NASDAQ:VERV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. www.defenseworld.net/2022/05/10/verve-therapeutics-nasdaqverv-lifted-to-hold-at-zacks-investment-research.html

翻译

Verve Therapeutics (NASDAQ:VERV) Lifted to Hold at Zacks Investment Research

www.defenseworld.net

Verve Therapeutics (NASDAQ:VERV – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course […]